A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs
Clinical trial NCT03355872 · COMPLETED
Trial details
- NCT number
- NCT03355872
- Sponsor
- Shanghai Henlius Biotech
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-02-01
- Primary completion
- 2018-08-01
- Enrollment
- 194
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.